Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Humana’s PDP membership shrinking

Executive Summary

Humana projects it will lose 1.1 million to 1.2 million members from its stand-alone Medicare prescription drug plans in 2009, due mainly to sharply higher premiums. The estimate includes auto-assigned members who were reassigned to plans with premiums below the low-income benchmark and low-income members who had voluntarily chosen Humana's plans, but who have now left to find less expensive coverage. Humana has backed away from coverage for low-income seniors because that business is too much of a drain on profits (1"The Pink Sheet," Sept. 15, 2008, p. 26). The firm's stand-alone PDP membership now totals about 2.1 million

You may also be interested in...



Humana Bows Out Of Medicare Part D Coverage For Dual Eligibles

In 2009, Humana will complete its exit from providing Medicare Part D benefits to low-income seniors who qualify for both Medicaid and Medicare coverage

Rejection Rate Soars In Q4 For EU Fast-Track Requests

October and November 2020 were bad months for companies seeking to have their planned EU filings fast-tracked through the centralized drug review system at the European Medicines Agency.

Biden Regulatory Freeze May Pause SUNSET Rule

Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.

Topics

UsernamePublicRestriction

Register

LL1135489

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel